American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly

Endocrine Practice

Volumn 10, Issue 3, 2004, Pages 213-225

  Cook, David M ^a   Ezzat, Shereen ^a   Katznelson, Laurence ^a   Kleinberg, David L ^a   Laws Jr , Edward R ^a   Nippoldt, Todd B ^a   Swearingen, Brooke ^a   Vance, Mary Lee ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547651880     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.3.213     Document Type: Review

References (73)

1. Fazio S, Cittadini A, Cuocolo A, et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab. 1994;79:441-446.
2. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000;85:3132-3140.
3. Grunstein RR, Ho KK, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med. 1994;121:478-483.
4. Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf). 1999;51:611-618.
5. Bari D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13:395-400.
6. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer [erratum in Cancer. 1992;69:549]. Cancer. 1991;68:1673-1677.
7. Renehan AG, Odwyer ST, Shalet SM. Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf). 2001;55:731-733.
8. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327-335.
9. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 1980;12:71-79.
10. Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998; 83:3419-3426.
11. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667-674.
12. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998;83:3411-3418.
13. Melmed S. Tight control of growth hormone: an attainable outcome for acromegaly treatment. J Clin Endocrinol Metab. 1998;83:3409-3410.
14. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med. 1979;301:1138-1142.
15. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26:481-512.
16. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69-73.
17. Winer LM, Shaw MA, Baumann G. Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. J Clin Endocrinol Metab. 1990;70:1678-1686.
18. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab. 1998;83:3808-3816.
19. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526-529.
20. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002;87:3537-3542.
21. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86:4072-4077.
22. Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg. 1993;78:205-215.
23. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998;89:353-358.
24. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly - the experience of a dedicated pituitary surgeon. QJM. 1999;92:741-745.
25. Clayton RN. How many surgeons to operate on acromegalic patients? Clin Endocrinol (Oxf). 1999;50:557-559.
26. Clayton RN, Stewart PM, Shalet SM, Wass JA. Pituitary surgery for acromegaly: should be done by specialists. BMJ. 1999;319:588-589.
27. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50:561-567.
28. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery. 1997;40:225-236.
29. Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 1996;81:2356-2362.
30. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study [erratum in J Clin Endocrinol Metab. 1995;80:3238]. J Clin Endocrinol Metab. 1995;80:2768-2775.
31. Ben-Shlomo A, Melmed S. Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab. 2003; 88:963-968.
32. Jho HD. Endoscopic transsphenoidal surgery. J Neurooncol. 2001;54:187-195.
33. Cappabianca P, Cavallo LM, Colao A, et al. Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg. 2002;45:193-200.
34. Cappabianca P, de Divitiis E. Image guided endoscopic transnasal removal of recurrent pituitary adenomas. Neurosurgery. 2003;52:483-484.
35. Bohinski RJ, Warnick RE, Gaskill-Shipley MF, et al. Intraoperative magnetic resonance imaging to determine the extent of resection of pituitary macroadenomas during transsphenoidal microsurgery. Neurosurgery. 2001;49: 1133-1143.
36. Fahlbusch R, Ganslandt O, Buchfelder M, Schott W, Nimsky C. Intraoperative magnetic resonance imaging during transsphenoidal surgery. J Neurosurg. 2001;95: 381-390.
37. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3034-3040.
38. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med. 1992;117:711-718.
39. Chanson P, Leselbaum A, Blumberg J, Schaison G (French Multicenter Study Group on Lanreotide in Acromegaly). Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly: a 12-month multicenter study of 58 acromegalic patients. Pituitary. 2000;2:269-276.
40. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86:2779-2786.
41. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphologic variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol. 1995;133:686-690.
42. Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract. 2001;7:170-180.
43. Colao A, Marzullo P, Spiezia S, et al. Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. J Clin Endocrinol Metab. 2000;85:3754-3761.
44. Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf). 2001;55:477-483.
45. Lombardi G, Colao A, Ferone D, et al. Cardiovascular aspects in acromegaly: effects of treatment. Metabolism. 1996;45(8 Suppl 1):57-60.
46. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 2002;87:4554-4563.
47. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol. 2001;145:137-145.
48. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754-1759.
49. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-1177.
50. Clemmons DR, Chihara K, Freda PU, et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab. 2003;88:4759-4767.
51. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83:374-378.
52. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol. 1998;139:516-521.
53. Flogstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 1997;82:23-28.
54. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg. 1998;88:1002-1008.
55. Pollock BE, Nippoldt TB, Stafford SL, Foote RL, Abboud CF. Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg. 2002;97:525-530.
56. Jane JA, Vance ML, Woodburn CJ, Laws ER Jr. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg Focus. 2003;14:1-5.
57. Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992;21:693-712.
58. Thalassinos NC, Tsagarakis S, Ioannides G, Tzavara I, Papavasiliou C. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol. 1998;138:160-163.
59. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary radiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997;82:3187-3191.
60. Flickinger JC, Rush SC. Linear accelerator therapy of pituitary adenomas. In: Landolt AM, Vance ML, Reilly PL, eds. Pituitary Adenomas. London, England: Churchill Livingstone, 1996: 475-483.
61. Giovanelli M, Losa M, Mortini P. Acromegaly: surgical results and prognosis. In: Landolt AM, Vance ML, Reilly PL, eds. Pituitary Adenomas. London, England: Churchill Livingstone, 1996: 333-351.
62. Bluestone R, Bywaters EG, Hartog M, Holt PJ, Hyde S. Acromegalic arthropathy. Ann Rheum Dis. 1971;30:243-258.
63. Detenbeck LC, Tressler HA, O'Duffy JD, Randall RV. Peripheral joint manifestations of acromegaly. Clin Orthop. 1973;91:119-127.
64. Dons RF, Rosselet P, Pastakia B, Doppman J, Gorden P. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol (Oxf). 1988;28:515-524.
65. Fatti LM, Scacchi M, Pincelli AI, Lavezzi E, Cavagnini F. Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary. 2001;4:259-262.
66. From the Centers for Disease Control and Prevention. Recommended adult immunization schedule - United States, 2002-2003. JAMA. 2002;288:2258-2260.
67. Colao A, Spinelli L, Marzullo P, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab. 2003; 88:3196-3201.
68. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab. 1997;82:2777-2781.
69. National Heart, Lung, and Blood Institute, National Institutes of Health. Clinical practice guidelines for high blood pressure. 2003. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm.
70. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.
71. Orme SM, McNally RJ, Cartwright RA, Belchetz PE (United Kingdom Acromegaly Study Group). Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998;83:2730-2734.
72. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly: clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994;73:233-240.
73. American Cancer Society. Cancer reference information. 2003. Available at: http://www.cancer.org/docroot/CRI/content/CRI-2-4-3X-Can-colon- and-rectum-cancer-be -found-early.asp?sitearea=CRI.